A recent study reveals that individuals who stop using blockbuster GLP-1 drugs like Mounjaro or Wegovy can put back on reduced body mass far faster than those who halt conventional lifestyle regimens.
Published data in a prominent medical journal demonstrates that while obese individuals often shed substantial amounts of their body weight while undergoing treatment, the mass comes back at an average rate of nearly a kilo each month upon discontinuation.
"Individuals using such treatments should be informed of the danger of fast rebound weight gain when the therapy ends," stated lead investigator Dr. Susan Jebb.
That rate of regain implies a reversion to starting weight within about one and a half years.
Analyzing Approaches
The study, which examined dozens of studies involving thousands of participants, compared the effects of these new drugs with conventional dieting.
Scientists emphasize that people who lose weight through diet and exercise typically see a less rapid creep back—perhaps 100 grams monthly—once they finish.
Understanding the Rapid Regain
Nutrition scientists propose the way of the jabs explains the amplified rebound.
These medications copy a natural hormone called glucagon-like peptide-1, which helps regulate feelings of fullness.
"Artificially providing GLP-1 concentrations far above than normal might result in the body to produce less of its endogenous hormone, and may also lessen sensitivity to its effects," said Dr. Adam Collins, a nutrition researcher.
"Withdrawal of this medication leads to hunger is no longer kept in check, making binge eating far more likely."
A Chronic Issue?
The NHS advise the injections for individuals with obesity-related health risks, accompanied by prescribed lifestyle changes.
Many experts argue that, given the likelihood of weight regain, the therapy might need to be long-term.
This opinion is reinforced by drug manufacturers, who state that the findings "emphasize the long-term nature of excess weight," akin to managing diseases like high blood pressure.
User Experiences
People who have discontinued the jabs explain a intense return of cravings.
"It felt as if a trigger that goes on and you're instantly ravenous," described an individual.
The struggle is worsened if users have not established sustainable lifestyle or habit changes during treatment.
Significant Interest
Figures show that a significant number of adults in the UK have used weight-loss jabs in the past year, with interest remaining high.
- Use is more common among females than men.
- The 40s and 50s demographic shows the highest usage rates.
- Many access the drugs through private healthcare rather than public health services.
Finally, clinicians caution that while GLP-1 drugs are effective agents for weight loss, they are not a standalone fix and maintained weight loss hinges on combined lifestyle management.
